Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab and Dupilumab in Early-stage, Resectable NSCLC
NCT06743581Phase 2Recruiting
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab and dupilumab in non-small cell lung cancer (NSCLC), sponsored by Centre hospitalier de l’Université de Montréal. Primary endpoints: Safety (Dose-limiting toxicities) at 30 days and Efficacy (Major Pathological Response Rate). Started Aug 2025; status: recruiting.
02
Drugs
cemiplimabdupilumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06743581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06743581.